iCasp9-transduced donor T cells

iCasp9-transduced donor T cells are genetically modified donor-derived T lymphocytes engineered to express the inducible caspase 9 (iCasp9) suicide/safety switch gene. Developed for use in myeloablative haploidentical allogeneic peripheral blood stem cell transplantation, these cells are infused to enhance immune reconstitution and provide a graft-versus-leukemia effect. The retrovirally introduced iCasp9 construct serves as a safety mechanism; if clinically significant graft-versus-host disease (GVHD) develops, the small-molecule dimerizing drug AP1903 (rimiducid) can be administered. AP1903 binds to the engineered FKBP12-F36V domain fused to caspase 9, triggering rapid dimerization and apoptosis of the transduced T cells, thereby mitigating GVHD. This cell-based gene therapy has been evaluated in a Phase 1 clinical trial sponsored by Metro North Hospital and Health Service – Royal Brisbane and Women's Hospital for high-risk hematologic malignancies, including acute myeloid leukemia (AML), acute lymphoblastic leukemia (ALL), chronic myeloid leukemia (CML), and myelodysplastic syndrome (MDS).

Other names

rivogenlecleuceliCasp9-modified donor T cellsiCasp-9-modified donor T cellsiCasp 9-modified donor T cellsiCasp9-transduced T cellsiCasp-9-transduced T cellsiCasp 9-transduced T cells